Key result
Glycoprotein IIb-IIIa receptor antagonists demonstrate benefits over conventional antiplatelet therapy in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes.
Why the study?
Do glycoprotein IIb-IIIa receptor antagonists improve outcomes in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes compared to conventional antiplatelet therapy?
Do glycoprotein IIb-IIIa receptor antagonists improve outcomes in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes compared to conventional antiplatelet therapy?
Glycoprotein IIb-IIIa receptor antagonists provide clinical benefits over conventional antiplatelet therapy in patients undergoing percutaneous coronary angioplasty and those with acute coronary syndromes.
Answers are grounded in this paper and cite their sources.
Supports adjunctive GP IIb/IIIa use in PCI and ACS; extends prior data but warrants reevaluation with modern regimens.
Platelet aggregation is mediated by the glycoprotein IIb-IIIa receptor, a member of the integrin superfamily of membrane-bound adhesion molecules. In the activated platelet, binding to the major adhesive proteins, fibrinogen and von Willebrand, occurs due to a conformational change of the glycoprotein IIb-IIIa receptor. Glycoprotein IIb-IIIa receptor antagonists effectively block the binding of these adhesive proteins and thus inhibit platelet aggregation. Large-scale clinical trials have demonstrated the benefits of these agents in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes compared to conventional antiplatelet therapy. Furthermore, trials are in progress in patients with acute myocardial infarction. The beneficial effects of these agents was first demonstrated with abciximab, a monoclonal antibody to the glycoprotein IIb-IIIa receptor, in patients at risk of coronary arterial thrombosis, and was further illustrated in trials with other IIb-IIIa receptor blocking agents, both with synthetic peptide and non-peptide receptor antagonists. This review focuses on the glycoprotein IIb-IIIa receptor antagonists most advanced in clinical development.
No takes yet. Share an insight, caveat, or question.
Winkelmann et al. (1997) conducted a review in Acute coronary syndromes and percutaneous coronary angioplasty. Glycoprotein IIb-IIIa receptor antagonists vs. Conventional antiplatelet therapy was evaluated. Glycoprotein IIb-IIIa receptor antagonists demonstrate benefits over conventional antiplatelet therapy in patients undergoing percutaneous coronary angioplasty and with acute coronary syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: